SCHEMBL21064056

SCHEMBL21064056

CCC1CC(=O)CC(C)N1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
CETP P11597 4/20 0.38
NR1H2 P55055 1/20 0.34
PREP P48147 3/20 0.33
GLA P06280 1/20 0.33
ABCB1 P08183 1/20 0.33
HSD11B1 P28845 1/20 0.32
DDB1 Q16531 1/20 0.32
CRBN Q96SW2 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13845952 1.00 CHRM2 (0.40) CHRM2CHRM1CHRM3CETPNR1H2
SCHEMBL24212059 1.00 CHRM2 (0.40) CHRM2CHRM1CHRM3CETPNR1H2
SCHEMBL4038626 0.91 CETP (0.44) CHRM2CHRM1CHRM3CETPNR1H2
SCHEMBL4071602 0.91 CETP (0.44) CHRM2CHRM1CHRM3CETPNR1H2
SCHEMBL14319923 0.91 CETP (0.44) CHRM2CHRM1CHRM3CETPNR1H2
SCHEMBL759059 0.91 CETP (0.44) CHRM2CHRM1CHRM3CETPNR1H2
SCHEMBL759308 0.91 CETP (0.44) CHRM2CHRM1CHRM3CETPNR1H2
SCHEMBL31699337 0.88 NR1H2 (0.40) CHRM2CHRM1CHRM3NR1H2PREP
SCHEMBL24874973 0.86 CHRM2 (0.36) CHRM2CHRM1CHRM3CETPNR1H2
SCHEMBL13096648 0.85 CHRM2 (0.47) CHRM2CHRM1CHRM3NR1H2PREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210009519-A1 HISTONE DEACETYLASE INHIBITORS BIOMARIN PHARMACEUTICAL INC. 2021-01-14 US disclosed
US-10851058-B2 Histone deacetylase inhibitors BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-01 US disclosed
US-10308608-B2 Histone deacetylase inhibitors BIOMARIN PHARMACEUTICAL INC. (US) 2019-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851058-B2 Histone deacetylase inhibitors HDAC1, HDAC2, HDAC3 CHRM2 4836/4885CHRM1 4856/4885CHRM3 4783/4885
US-20210009519-A1 HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC2, HDAC3 CHRM2 4836/4885CHRM1 4856/4885CHRM3 4783/4885
US-10308608-B2 Histone deacetylase inhibitors HDAC1, HDAC2, HDAC3 CHRM2 4836/4885CHRM1 4856/4885CHRM3 4783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.